CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Revenue:
Total revenue	$ 216,833	$ 101,620	$ 519,147	$ 282,345
Costs and operating expenses:
Selling and marketing expense	41,267	36,758	123,355	115,077
General and administrative expense (see note 10)	51,973	40,852	168,458	126,273
Research and development expense	21,624	27,644	69,739	86,807
Total costs and operating expenses	184,191	162,462	562,445	502,421
Income (Loss) from operations	32,642	(60,842)	(43,298)	(220,076)
Other expense, net:
Interest income	7,360	1,744	9,482	6,152
Interest expense	(13,507)	(13,799)	(45,497)	(36,763)
Changes in fair value of financial instruments	(2,081)	5,131	(52,285)	6,067
Other income (expense), net	(89)	37	(18,447)	(323)
Total other expense, net	(8,317)	(6,887)	(106,747)	(24,867)
Income (Loss) before income taxes and provision for income taxes	24,325	(67,729)	(150,045)	(244,943)
Provision for income taxes	0	0	0	0
Net income (loss)	24,325	(67,729)	(150,045)	(244,943)
Other comprehensive income, net of tax:
Unrealized gain on available-for-sale securities	0	0	0	7
Foreign currency translation adjustments	79	(120)	538	(20)
Comprehensive income (loss)	24,404	(67,849)	(149,507)	(244,956)
Net income (loss)	24,325	(67,729)	(150,045)	(244,943)
Deemed dividend from Series D redeemable convertible preferred stock (see note 6)	0	0	(384,436)	0
Adjustments of redeemable convertible preferred stock to redemption value	0	(24,661)	(85,433)	(71,368)
Net income (loss) attributable to common shareholders basic	24,325	(92,390)	(619,914)	(316,311)
Net income (loss) attributable to common shareholders diluted	$ 24,325	$ (92,390)	$ (619,914)	$ (316,311)
Net income (loss) per share attributable to common shareholders:
Basic (in dollars per share)	$ 0.09	$ (2.59)	$ (4.83)	$ (8.92)
Diluted (in dollars per share)	$ 0.08	$ (2.59)	$ (4.83)	$ (8.92)
Weighted-average shares used in computing net income (loss) per share attributable to common shareholders:
Basic (in shares)	282,099,073	35,643,589	128,447,673	35,442,927
Diluted (in shares)	297,211,838	35,643,589	128,447,673	35,442,927
Molecular Profiling Services
Revenue:
Total revenue	$ 207,587	$ 93,803	$ 484,593	$ 254,692
Costs and operating expenses:
Cost of services	66,980	54,810	193,195	167,134
Pharma Research And Development Services
Revenue:
Total revenue	9,246	7,817	34,554	27,653
Costs and operating expenses:
Cost of services	$ 2,347	$ 2,398	$ 7,698	$ 7,130